Clearmind Medicine (CSE:CMND) recently announced additional positive preclinical data related to its psychedelic molecule 5-methoxy-2-aminoindane (MEAI) for treating cocaine addiction. Professor Gal Yadid and a group of researchers from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) performed the study based on the self-administration paradigm, which is an operant-conditioning-based…
Clearmind aims to use a psychedelic to treat alcoholism
The psychoactive compound 5-methoxy-2-aminoindane (MEAI) is unique among psychedelics with therapeutic potential. First, the drug could be self-administered. Second, it is patented, unlike psychedelics such as LSD, psilocybin, MDMA and ketamine. And while psychedelic drug developers tend to focus on indications such as depression, anxiety and post-traumatic stress disorder, MEAI could potentially treat alcoholism. MEAI…